RAS is one of the most well-known proto-oncogenes. Its gain-of-function mutations occur in
approximately 30% of all human cancers. As the most frequently mutated RAS isoform …

The mechanism by which the wild-type KRAS allele imparts a growth inhibitory effect to
oncogenic KRAS in various cancers, including lung adenocarcinoma (LUAD), is poorly …

Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

Mutations of the KRAS gene are found in human cancers with high frequency and result in
the constitutive activation of its protein products. This leads to aberrant regulation of …

KRAS gain-of-function mutations occur in approximately 30% of all human cancers. Despite
more than 30 years of KRAS-focused research and development efforts, no targeted therapy …

Cancers of nearly all lineages harbor alterations that deregulate mitogen-activated protein
kinase signaling, a crucial signaling pathway for tumor formation and maintenance. Of these …

After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …

KRAS mutations occur in one third of human cancers and cluster in several hotspots, with
codons 12 and 13 being most commonly affected. It has been suggested that the position …

KRAS can bind numerous effector proteins, which activate different downstream signaling
events. The best known are RAF, phosphatidylinositide (PI)-3′ kinase, and RalGDS …